Gain Therapeutics (GANX) announced that a guided poster presentation was made at the International Association of Parkinsonism and Related Disorders 30th World Congress on Parkinson’s Disease and Related Disorders, held May 7th-10th in New York City, NY. The poster outlined new evidence supporting GT-02287’s ability to provide a broader neuroprotective effect and potential as a disease-modifying therapy for Parkinson’s disease. Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+ Summary: In cultured rat mesencephalic dopaminergic neurons treated with MPP+, a mitochondrial toxin that induces mitochondrial impairment by inhibiting mitochondrial complex 1, GT-02287 improved the function of both the lysosomes and mitochondria and exerted a broader neuroprotective effect. GT-02287 lowered alpha-synuclein aggregation, lysosomal dysfunction, and mitochondrial stress while also preventing the release of mitochondrial cytochrome C, a programmed cell death signal, thereby promoting neuronal survival.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
- Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating
- Gain Therapeutics Unveils New Parkinson’s Treatment Data
- Gain Therapeutics presents additional data on study of GT-02287
- Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position